AVBP.US ArriVent BioPharma, Inc. Common Stock

Healthcare Biotechnology USA Stocks
13.01 USD
Close of Nov 14, 2026
11.36 35.83
Market cap
USD 673M
P/E
-
P/B
1.72x
ROE
-43.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2026.

Is AVBP.US undervalued?

Graham number

The Graham number of ArriVent BioPharma, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ArriVent BioPharma, Inc. Common Stock fundamental analysis

No fundamental analysis for ArriVent BioPharma, Inc. Common Stock yet.

ArriVent BioPharma, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ArriVent BioPharma, Inc. Common Stock

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical …

Full company profile